1. Introduction {#s0005}
===============

Rheumatoid arthritis is an autoimmune disorder that causes inflammation of joints such as knees, ankles, hands and feet which leads to swelling, pain and immobility ([@b0005]). Treatment options available to treat this disease include nonsteroidal anti-inflammatory drugs (NSAID), corticosteroids, disease-modifying anti-rheumatic drugs (DMARD) and injectable biologics. Baricitinib, a new sub-class of DMARD, has recently been approved as oral immediate release tablets by USFDA for the treatment of rheumatoid arthritis especially for the patients not responding to the available therapies ([@b0050]). It is a selective inhibitor of Janus kinase 1 and 2 (JAK 1 and JAK 2). Janus kinases are group of enzymes that activate signal transducers and activators of transcription enabling the inflammation and immune function ([@b0020]). Baricitinib is an aromatic polyheterocyclic compound ([Fig. 1](#f0005){ref-type="fig"}a) with molecular formula and molecular weight as C~16~H~17~N~7~O~2~S and 371.42 respectively ([@b0020]). As per assessment report, baricitinib belongs to class III of biopharmaceutical classification system (BCS), which means that it is highly soluble and poorly permeable drug, however, the same report also mentioned that baricitinib is practically insoluble. ([@b0020]). Nevertheless, it has been reported to have both solubility (0.357 mg/ml of water) as well as permeability (Log P = 1.08) challenges as per drugbank identification report ([@b0055]). Baricitinib has been reported to be soluble in organic solvents such as dimethyl sulphoxide (74 mg/ml), dimethyl formamide (50 mg/ml) but very poorly soluble in water and ethanol (\<1 mg/ml at 25 °C) ([@b0030]). Another product information on baricitinib reported poor aqueous solubility of baricitinib (∼0.5 mg/ml in 1:1 mixture of phosphate buffer saline pH 7.2: dimethyl formamide) while solubility in organic solvents like such as dimethyl sulphoxide and dimethyl formamide was ∼50 mg/ml ([@b0110]). Drugs with poor solubility or permeability suffer with low and or inconsistent bioavailability affecting the performance and therapeutic goals ([@b0040]). Moreover, low bioavailability necessitates administration of higher doses that may lead to side effects. Oral bioavailability of aqueous solution of baricitinib in 0.5% methylcellulose was reported as 48% in dogs, 54% in rats, 47--68% in monkey and 79% in human ([@b0020]). Pharmacokinetic parameters such as Cmax, Tmax, AUC0-∞, total clearance and elimination half-life after oral administration of baricitinib in healthy volunteer were reported as ∼112 nM, ∼1h, 740 nM × h, ∼17 L/h and ∼8 h respectively ([@b0020]). The inter-subject variability of pharmacokinetic parameters was reported to be moderate with a range between 17 and 26% in healthy volunteers while in patients with rheumatoid arthritis it was as high as 41% ([@b0020]).Fig. 1Molecular structures of (a) baricitinib and (b) Poly (lactic-co-glycolic acid), n = number of units of lactic acid; m = number of units of glycolic acid.

There are various techniques to improve solubility and bioavailability of such drugs. Polymeric nanoparticles based on PLGA ([Fig. 1](#f0005){ref-type="fig"}b) have been investigated extensively for the enhancement of solubility or bioavailability of poorly soluble drugs due to certain advantages such as biodegradable and biocompatible nature of the copolymer. Moreover, it is non-immunogenic, nontoxic, and approved by FDA for various biomedical and pharmaceutical applications ([@b0100]). The recent literature search revealed that PLGA is one of the most widely used polymeric materials employed for the fabrication of nanoparticles. It has been reported to enhance solubility and bioavailability of several poorly soluble drugs such as resveratrol ([@b0135]), nelfinavir ([@b0140]), lopinavir ([@b0095]), docetaxel ([@b0120]) and benzophenone ([@b0035]).

This study has been undertaken to develop and evaluate baricitinib encapsulated PLGA nanoparticles to improve dissolution and performance of the drug. There is no report on the investigation of solubility or bioavailability of baricitinib encapsulated PLGA nanoparticles.

2. Materials and methods {#s0010}
========================

2.1. Materials {#s0015}
--------------

Baricitinib was purchased from Mesochem Technology Co Ltd (Beijing, China). PLGA polymer (50:50), Pluronic acid 127 and was purchased from Sigma--Aldrich (St. Louis, MO). Acetone (AC), acetonitrile (AN), dichloromethane (DCM), ethylacetate (EA) and tetrahydrofuran (THF) were of analytical grade and were purchased from Sigma--Aldrich (St. Louis, MO). Deionized water was obtained from Milli-Q, Millipore, Massachusetts USA.

2.2. Methods {#s0020}
------------

The research methodology employed a quantitative research utilizing experimental design wherein effect of the dependent variables such as nanoparticle size, size distribution (polydispersity index-PDI), zeta potential and entrapment efficiency over the independent variables such as amount of polymer, drug, type of solvent, and solvent: anti-solvent ratio were investigated.

2.3. Formulation of baricitinib encapsulated nanoparticles {#s0025}
----------------------------------------------------------

Baricitinib encapsulated PLGA nanoparticles were prepared by nanoprecipitation method which involves precipitation of insoluble drugs in the aqueous phase when an organic solution of drug and polymer mixture is added slowly to the aqueous phase kept on moderate stirring ([@b0070]). Definite amount of baricitinib and PLGA were dissolved in suitable organic solvent which was then added dropwise in anti-solvent kept over moderate stirring of 700 rpm. The mixture was stirred over night to remove the organic solvent that rendered hardening of nanoparticles. Nanosuspension was centrifuged at 15000 × rcf (Centurion scientific, UK) for 30 min to separate the nanoparticles, which was then washed with cold water and freeze- dried (Mill rock technology, Kingston, NY) for further analyses.

### 2.3.1. Effect of solvent {#s0030}

Various organic solvents like acetone (AC), acetonitrile (AN), dichloromethane (DCM), ethyl acetate (EA) and tetrahydrofuran (THF), were investigated to optimize the organic phase for nanoprecipitation. Accurately weighed PLGA (50 mg) and baricitinib (10 mg) was dissolved separately in 10 ml of each organic solvent to prepare different formulation with formulation codes (F1--F5) as presented in [Table 1](#t0005){ref-type="table"}. The prepared organic phases were added dropwise to the 50 ml of anti-solvent (1% aqueous pluronic 127) kept over magnetic stirrer rotating at 700 RPM.Table 1Formulation codes and composition of nanoparticles containing 10 mg of baricitinib and 50 mg of PLGA.Formulation numberOrganic solventFormulation codeF1AcetoneACF2AcetonitrileANF3DichloromethaneDCMF4Ethyl acetateEAF5Tetra hydro furanTHF

### 2.3.2. Effect of anti-solvent {#s0035}

To investigate the effect of anti-solvent on nanoprecipitation, different ratio of solvent: anti-solvent (1:2, 1:3, 1:5 and 1:10) were investigated for optimization of the nanoparticles. Accurately weighed baricitinib (10 mg) and PLGA (50 mg) were dissolved in 10 ml of acetone as a solvent for both drug and polymer. The deionized water was used as anti-solvent containing 1% pluronic 127 as stabilizer. The composition of the formulations (F6-F9) are presented in [Table 2](#t0010){ref-type="table"}.Table 2Formulation codes and composition of nanoparticles containing 10 mg of baricitinib and 50 mg of PLGA prepared with varying solvent and anti-solvent ratio.Formulation numberFormulation codeSolvent (ml)Anti-solvent (ml)F6S:AS/1:21020F7S:AS/1:31030F8S:AS/1:51050F9S:AS/1:1010100

### 2.3.3. Effect of polymer {#s0040}

To investigate the effect of polymer on the formulation characteristics, the polymer concentration was varied in the range between 1 and 10 mg/ml of acetone. The organic phase containing 10 mg of baricitinib and different amount of PLGA in the range of 1--10 mg/ml were prepared in 10 ml of acetone to have different formulations (F10--F13) as presented in [Table 3](#t0015){ref-type="table"}. The prepared organic phases were then added dropwise to the 50 ml of anti-solvent (1% aqueous pluronic 127) kept over magnetic stirrer rotating at 700 RPM.Table 3Formulation codes and composition of nanoparticles containing 10 mg of baricitinib and varying amounts of PLGA dissolved in 10 ml of acetone.Formulation numberFormulation codepolymer concentration (mg/ml)polymer amount (mg)F10PLGA 1110F11PLGA 2220F12PLGA 3330F13PLGA 1010100

### 2.3.4. Effect of drug {#s0045}

The effect of drug on the particle size, size distribution and zeta potential were investigated by preparing formulations with or without drug and or polymer. The composition of the formulations (F14--F16) are presented in [Table 4](#t0020){ref-type="table"}. The component (s) were dissolved in 10 ml of acetone to prepare organic phases (except F-16, which was prepared by suspending 10 mg of baricitinib in 1% pluronic 127 for comparison purpose). The prepared organic phases were added dropwise to the 50 ml of anti-solvent (1% aqueous pluronic 127) kept over magnetic stirrer set at 700 RPM.Table 4Formulation codes and composition of nanoparticles with or without baricitinib and or PLGA dissolved in 10 ml of acetone.Formulation numberFormulation codeBaricitinib (mg)PLGA (mg)F14D:P/1:0100F15D:P/0: 1010[\*](#tblfn1){ref-type="table-fn"}F16D: P/1:0100[^1]

2.4. Optimization of nanoparticles {#s0050}
----------------------------------

The prepared nanoparticle formulations were optimized on the basis of visual appearance (agglomeration), particle size, size distribution (polydispersity index), zeta potential and % entrapment efficiency.

### 2.4.1. Particle size and size distribution {#s0055}

The particle size and size distribution was investigated by dynamic light scattering (DLS) technique, wherein fluctualtions in the intensity of scattered light is measured as a function of movement (diffusion) of nanoparticles. The smaller the nanoparticles, the faster will be the diffusion (Brownian motion), as described by Eq. [(1)](#e0005){ref-type="disp-formula"}, derived from Stoke-Einstein diffusion equation (Eq. [(2)](#e0010){ref-type="disp-formula"}). Faster diffusion of the nanoparticles result in rapid fluctualtions in the scattered light. These fluctuations in the scattered light is then measured by a photon counter and correlated with the diffusion coefficient of nanoparticle (hydrodynamic size of nanoparticle) therefore DLS technique is also called as photon correlation spectroscopy (PCS). In this study, we employed state of the art equipment, Zetasizer Nano ZS, model ZEN3500 (Malvern Instruments, UK), for particle size and size distribution measurement. It utilizes a patented non-invasive back scatter (NIBS) technology that measures the scattered light at a backscatter angle of 173° improving it's sensitivity and measuring capacity. The nanoparticles (∼5 mg) were suspended in 10 ml of deionized water by vortex mixing for 30 s followed by ultrasonication for 60 s to break agglomerates if any. Appropriate volume, approximately 2 ml of the prepared nanoparticle suspension was taken in the disposable plastic cuvette. Particle size was then measured in triplicate at 25 °C. The size of nanopartilces is reported as Z-average diameter (Eq. [(3)](#e0015){ref-type="disp-formula"}), an intensity based harmonic mean diameter calculated by cumulant analysis using least squares fitting, therefore considered as relatively insensitive to experimental noise ([@b0075]).$$R = \frac{k_{B}T}{6\pi\eta D}$$where,R = Hydrodynamic radius of the nanoparticle,k~B~ = Boltzman's constant,T = Temperature,η = Viscosity of the dispersion medium,D = Diffusion coefficient$$D = \frac{k_{B}T}{6\pi\eta R}$$$$\mathit{Dz} = \frac{\sum Si}{\sum(Si/Di)}$$whereDz = Z average diameter,Si = Scattered intensity from nanoparticle iDi = Diameter of nanoparticle i.

### 2.4.2. Evaluation of zeta potential of nanoparticle suspension {#s0060}

The zeta potential of disperse systems such as nanoemulsions and nanosuspensions is one of the very important characteristics that helps in stability of the dispersions. It is potential difference across the phase boundaries between dispersed phase and dispersion medium. It is considered as an index of repulsion, thus higher the zeta potential, higher will be repulsion between the dispersed particles with similar charges resulting in more stable dispersions. The magnitude of zeta potential mainly depends on the charges over the dispersed phase and in the dispersion medium, which in turn is influenced by dielectric constant/ionic strength, conductivity, viscosity and pH of the dispersion medium as described by Henry equation (Eq. [(4)](#e0020){ref-type="disp-formula"}). Therefore, evaluation of the zeta potential of nanoparticle suspension becomes very important to predict its fate such as stability, transportation or absorption within the body/body tissues. Zeta potential of nanoparticles is determined experimentally by measuring the electrophoretic mobility of the nanoparticles i.e. measurement of velocity of nanoparticles moving towards electrodes under electrical fields. The higher the velocity, the higher will be the magnitude of zeta potential. In this study, we used zetasizer nano ZS (Malvern Instrument, UK) with patented mixed mode measurement, phase analysis light scattering (M3-PALS), which is capable of measuring mean zeta potential and zeta potential distribution with excellent accuracy. Briefly, the nanoparticles (∼5 mg) were suspended in 10 ml of 10 mM sodium chloride by vortex mixing (30 s) followed by ultrasonication for 60 s to break agglomerates if any. The appropriate volume (∼0.9 ml of nanosuspension) was then introduced with the help of syringe into specialized polycarbonate zeta cells (folded capillary cell with gold-plated electrodes, model DTS1017, Malvern Instruments) held in inverted position to avoid introduction of air bubbles. Caps for zeta cells were used to close the cell. Zeta potential was then measured in triplicate at 25 °C.$$\mu e = \frac{2z\varepsilon f(ka)}{3\eta}$$$\mu e$ = electrophoretic mobility,z = zeta potential,ε = dielectric constant,f(k a) = Henrys function; it equals to 1.5 (for polar dispersant); known as the Smoluchowski approximation.*η* = viscosity of the dispersion medium.

### 2.4.3. Drug entrapment efficiency of nanoparticles {#s0065}

The drug entrapment efficiency of the nanoparticle formulations was calculated by indirect method which involded sedimentation of nanoparticles by ultracentrifugation followed by analysis of unentrapped drug in the supernetant. The difference between the amount of drug added initially in the formulation and unentrapped drug found in the supernetant gives the amount of drug entrapped in formulation. Briefly, nanoparticle suspensions were centrifuged at 15000 × rcf for 30 min. The supernetant obtained was analyzed by bouble beam UV spectrophotometer (UV 630, Jasco, Japan) at 224 nm after appropriate dilution. The % entrapment efficiency of the formulation was calculated as mentioned in Eq. [(5)](#e0025){ref-type="disp-formula"}.$$\% Entrapment = \frac{\mathit{Drug}\ \mathit{loaded}\  - \ Drug\ found}{\mathit{Drug}\ \mathit{loaded}\ }X100$$

The drug loading capacity were calculated by direct method which involved comparison of practically loaded drug found in analysis of nanoparticle solution with that of theoretical amount of drug taken in beginning to load in the polymer (Eq. [(6)](#e0030){ref-type="disp-formula"}). Briefly, about 10 mg of dried nanoparticles were dissolved in acetone which was then diluted appropriately and analyzed by double beam UV spectrophotometer (UV 630, Jasco, Japan) at 224 nm.$$\% Drug\ loading = \frac{\mathit{Amount}\ \mathit{of}\ \mathit{drug}\ \mathit{found}}{\mathit{Amount}\ \mathit{of}\ d\mathit{rug}\ \mathit{and}\ \mathit{polymer}}X100$$

2.5. Characterization of baricitinib encapsulated PLGA nanoparticles {#s0070}
--------------------------------------------------------------------

The characterization of optimized nanoparticle was carried out by studying the size and surface morphology by Scanning Electron Microscopy (SEM), powder properties by X-ray Diffractrometry (XRD), Differential Scanning Calorimetry (DSC), Fourier Transform Infra Red spectroscopy (FT-IR), *in vitro* drug release studies and release mechanism.

### 2.5.1. Size and surface characterization {#s0075}

The size and surface of baricitinib encapsulated nanoparticles were characterized by Scanning Electron Microscopy (Zeiss EVO LS10; Cambridge, UK). The dried nanopartilces were suspended in one ml of deionized water and sonicated for 1 min to break the agglomeration if any. A drop of nanoparticle suspension was fixed on the carbon tape (SPI Supplies, West Chester, PA) and gold coated under vacuum (Q150R sputter coater, Quorum Technologies Ltd, East Sussex, UK) in an argon atmosphere at 20 mA for 60 s ([@b9000]).

### 2.5.2. X-ray diffractometry (X-RD) of nanoparticles {#s0080}

The X-ray diffractometry of the pure baricitinib and baricitinib encapsulated PLGA nanopartilces was conducted to compare powder characteristics before and after nanoencapsulation using Altima IV, X-ray diffractometer (Rigaku, Japan). The appropriate amount of dried nanopartilces and pure drug samples were placed on the XRD sample holder and pressed with help of glass slide. The X ray diffraction patterns at 2θ were then obtained by scanning the samples between 5° and 60° at a step size and step time of 0.02° and 0.5 s respectively ([@b0010]).

### 2.5.3. Differential scanning calorimetry (DSC) {#s0085}

The differential scanning calorimetry of the drug and drug encapsulated nanoparticles was carried out by using DSC-N 650 (SCINCO, Italy). Approximately 5 mg of pure drug sample and drug encapsulated nanoparticles were crimped into aluminum pans. Empty aluminum pan was crimped similarly to be used as reference material. The sample and the reference were then p laced in sample holder and scanned between 50 and 250 °C at a rate of 10 °C per minute with nitrogen gas flowing at 20 ml per minute.

### 2.5.4. Fourier transform infra-red spectroscopy (FT-IR) {#s0090}

Fourier transform infra-red spectroscopy of the drug and drug enclosed nanoparticles was conducted by using the potassium bromide (KBr) disc technique on the FT-IR instrument (FT/IR-4600, Jasco, Japan). Approximately 5 mg of drug or drug encapsulated nanoparticles was mixed and triturated with equal amount of KBr in mortar. The obtained mixtures were then compressed by Quick Press KBr pellet kit to obtain thin films. The sample film is mounted in sample holder and scanned between a wavenumber range of 400--4000 cm^−1^ after taking background scan.

### 2.5.5. *In vitro* release study {#s0095}

*In vitro* release study of nanoparticles was performed by sample and separate method ([@b0130]). The nanoparticle sample containing ∼10 mg drug was weighed and introduced into 25 ml of release media (phosphate buffer pH 6.8, containing 0.5% w/v of Sodium lauryl sulphate) kept on thermostated (37 ± 1 °C) biological shaker rotating at 100 RPM (LBS-030S-Lab Tech, Korea). An aliquot of 1 ml was sampled at 0, 0.5, 1, 2, 4, 8, 12, and 24 h after the addition of nanoparticles in release media. Fresh media was introduced after every sampling to maintain the sink condition. Withdrawn samples were centrifuged at 15,000 rcf for 30 min then analyzed by double beam UV spectrophotometrically at 224 nm. The release kinetics (mechanism of drug release) of nanoparticles were studied by fitting the release data to zero order, first order, Higuchi and Korsmeyer-Peppas plots ([@b0105]). The release rate constants k and n of the models were calculated by linear regression analysis.

3. Results and discussions {#s0100}
==========================

3.1. Formulation of baricitinib encapsulated PLGA nanoparticles {#s0105}
---------------------------------------------------------------

Fabrication of baricitinib encapsulated PLGA nanoparticles were achieved by nanoprecipitation method ([@b0070]). It is one of the simplest methods of fabrication of nanopartilces based on bottom up technology. It involved solubilization of baricitinb and PLGA in a suitable organic solvent followed by slow addition of the prepared organic phase into aqueous phase resulting in nanoprecipitation. We prepared several formulations and investigated the effect of various independent variables such as amount of PLGA, baricitinib: PLGA ratio, nature of organic solvent, and solvent: anti-solvent ratio on the fabrication of nanoparticles.

3.2. Optimization of baricitinib encapsulated nanoparticles {#s0110}
-----------------------------------------------------------

The development and optimization of nanoparticles were performed by investigating the effect of several independent variables such as amount of polymer, amount of drug, types of solvent and anti-solvent with varying ratio over the dependent variable such as size, size distribution, zeta potential and entrapment efficiency of nanoparticle suspension.

### 3.2.1. Effect of solvent {#s0115}

Several solvents were investigated to select the optimum solvent for nanoprecipitation based on absence of agglomeration and parameters such as nanoparticle size, size distribution, zeta potential and entrapment efficiency. Formulation 1 (F1) containing acetone was optimized and selected as solvent for polymer and drug based on absence of agglomeration, the lowest size (120 nm), smallest PDI (0.091), the highest zeta potential (−8.5 mv) and good entrapment efficiency ([Fig. 2](#f0010){ref-type="fig"}). The entrapment efficiency of formulation in acetonitrile (F-2) and dichloromethane (F-3) were higher with 93.2% and 91.9% respectively. However, these formulations were not chosen as optimum owing to larger nanoparticle size (PDI) of 964 nm (0.804) and 608 nm (0.643) for F-2 and F-3 respectively. The effect of solvent on the size, size distribution and entrapment efficiency of nanoparticles is not well understood. Smaller sizes of nanoparticles in formulation F-1 may be ascribed to better solubility of PLGA in acetone and better diffusion of acetone in the anti-solvent compared to other solvents. Moreover, low boiling point, high dielectric constant and high water miscibility of acetone may be advantageous in producing smaller size nanoparticles ([@b0085]).Fig. 2Effect of solvent on the size, poly dispersity index (PDI), zeta potential and entrapment efficiency of baricitinib encapsulated PLGA nanoparticles. AC -- acetone, AN -- acetonitrile, DCM -- dichloromethane, EA -- ethyl acetate and THF -- tertahydrofuron.

### 3.2.2. Effect of anti-solvent {#s0120}

Various ratio of solvent: anti-solvent (1:2, 1:3, 1:5 and 1:10) were tested for optimization of the nanoparticles based on size, PDI, zeta potential and entrapment efficiency. Decrease in the solvent:antisolvent ratio from 1:2 to 1:5 resulted in reduction of particle size and PDI but at the cost of loss in the entrapment efficiency. Further decrease in the phase ratio resulted in larger nanoparticles with higher entrapment efficiency. A solvent: antisolvent ratio of 1:5 (formulation number F-8) was chosen as the optimum formulation based on the smallest size (91 nm), the lowest PDI (0.169), the highest zeta potential value (−12.5) with entrapment efficiency of 88.0% ([Fig. 3](#f0015){ref-type="fig"}). The smaller sizes of nanoparticles at smaller solvent:antisolvent ratio could be attributed to low viscosity of the mixture and better diffusion of solvent in the antisolvent ([@b0125]).Fig. 3Effect of solvent: anti-solvent ratio on the size, poly dispersity index (PDI), zeta potential and entrapment efficiency of baricitinib encapsulated PLGA nanoparticles.

### 3.2.3. Effect of concentration of PLGA on nanoparticles {#s0125}

Organic solutions of PLGA with various concentration were investigated for optimization of the nanoparticles based on size, PDI, zeta potential and entrapment efficiency. Increasing concentration of polymer in organic solution resulted in increase in size and entrapment efficiency of the nanoparticles ([Fig. 4](#f0020){ref-type="fig"}). Formulation F-10 that contains the lowest concentration of PLGA (1 mg/ml of in acetone) resulted in the smallest nanoparticles (88 nm) but with the lowest entrapment efficiency (69.1%). Formulation F 14, with highest concentration of PLGA (10 mg/ml in acetone) exhibited the highest drug entrapment efficiency (90.8%) but at the cost of comparatively larger nanoparticles (158 nm). This increase in the size of nanoparticles, upon the increment of PLGA concentration in the acetone, may be due to the increased viscosity that might have reduced the diffusion of PLGA form acetone to the anti-solvent ([@b0015]).Fig. 4Effect of PLGA concentration on the size, poly dispersity index (PDI), zeta potential and entrapment efficiency of baricitinib encapsulated PLGA nanoparticles.

### 3.2.4. Effect of drug and polymer on the nanoparticles {#s0130}

The effect of drug on the particle size, size distribution and zeta potential was investigated by preparing formulations with or without drug and or polymer ([Fig. 5](#f0025){ref-type="fig"}). The nanoparticles of drug alone (formulation F-14) prepared by nanoprecipitation of organic solution of baricitinib resulted in large nanoparticles (427 nm) with high PDI (0.46) and low zeta potential (−8.6 mV). Similarly, nanoparticles of polymer alone (formulation F-15) prepared by nanoprecipitation of organic solution of PLGA resulted in larger nanoparticles (635 nm) with higher PDI (0.86) and lower zeta potential (−5.5 mV). The larger size of nanoparticles with very high PDI and very low zeta potential are indicative of particle growth or aggregation which could be due to absence of polymer. Polymeric materials present in organic phase (formulation F1--F13) prevent aggregation of nanosuspension by forming a layer around the nanoprecipitates once it is formed thus control and stabilize the size of particles. The mechanism of stabilization of size of nanoparticles could include either steric stabilization or electrostatic repulsion due to presence of surface charges or a combination of both. The drug suspension (F16) exhibited even poorer particle characteristics with average particle size of 935 nm, the highest PDI (0.96) and the lowest zeta potential value (−1.1 mV).Fig. 5Effect of the drug and or polymer on the size, poly dispersity index (PDI), zeta potential and entrapment efficiency of baricitinib encapsulated PLGA nanoparticles.

Based on the combined effect of types of solvent, solvent: anti-solvent ratio (phase ratio) and PLGA concentration (drug: polymer ratio) over the desired properties of nanoparticles such as the lowest size, the lowest PDI, the highest zeta potential and high entrapment efficiency, formulation F-8 was selected as optimized formulation for further evaluations. The smaller nanoparticles are known to be absorbed or up taken by mucosal cells better than their larger counterparts ([@b0145]). The particle size, PDI and zeta potential of nanoparticles were evaluated by zeta sizer nano ZS (Malvern, UK). An image of size analysis and zeta potential analysis of F-8 is presented in [Fig. 6](#f0030){ref-type="fig"} and [Fig. 7](#f0035){ref-type="fig"} respectively.Fig. 6Nanoparticle size analysis of formulation F8 obtained by Malvern zatasizer nano ZS.Fig. 7Nanoparticle zeta-potential analysis of formulation F 8 obtained by Malvern zatasizer nano ZS.

The characterization of nanoparticle suspension in term of zeta potential is one of most important tool for prediction of stability of dispersions. It is considered as an index of repulsion, thus the more is the value of zeta potential, the more will be stability of nano-suspension. A higher zeta potential means higher electric charge on the surface of the NPs that prevents aggregation of the nanoparticles. In the present investigation, we found an average zeta-potential of around −10.5 mV for all the prepared formulation with the value of −12.5 ± 5.6 mV for the optimized one (F-8). It has been reported that absolute Zeta potential values above 30 mV provide good stability ([@b0090]). However, large molecular weight solids or polymers are known to stabilize the suspensions by steric hindrance despite of low zeta potential ([@b0080]).

3.3. Characterization of nanoparticles {#s0135}
--------------------------------------

The characterization of optimized nanoparticle formulation (F-8) was carried out by studying the size and surface morphology by SEM, powder properties by XRD, FT-IR, DSC and drug release study and release mechanism.

### 3.3.1. Size and surface characterization {#s0140}

The size and surface of nanoparticles were further characterized by Scanning Electron Microscopy (Zeiss EVO LS10; Cambridge, UK). The SEM photographs of baricitinib encapsulated PLGA nanoparticles (F8) are shown in [Fig. 8](#f0040){ref-type="fig"}. The size of the nanoparticles were in the nanometer range while shape of the nanoparticles were found to be spherical. The sizes obtained in the SEM image are not consistent with those obtained in dynamic light scattering studies by zetasizer nano (Malvern, UK). The larger particles observed in the photomicrograph could be due to particle growth either during freeze drying or during sample preparation for imaging studies which involved dispersion of dried particles in the deionized water.Fig. 8Scanning Electron photomicrograph of baricitinib encapsulated PLGA nanoparticles (formulation F-8), Magnification:1390×, EHT: electron high tension; 5 kV, WD; working distance 8 mm.

### 3.3.2. X-ray diffraction study of baricitinib encapsulated nanoparticles {#s0145}

The X-ray diffraction study of pure baricitinib and baricitinib encapsulated nanoparticles were performed to investigate particle nature of baricitinib before and after encapsulation. The XRD spectra of pure baricitinib and baricitinib encapsulated nanoparticles are presented in [Fig. 9](#f0045){ref-type="fig"}. The spectrum of pure baricitinib exhibited several characteristics sharp peaks between 12.5 and 42.5° with very high intensity from 200 counts reaching upto 1600 counts. These peaks are indicative of crystalline nature of the baricitinib ([Fig. 9](#f0045){ref-type="fig"}a). However, the spectrum of PLGA ([Fig. 9](#f0045){ref-type="fig"}b) did not exhibited peaks which is indicative of non-crystalline nature of the polymer. It has been reported that PLGA composed of L isomers of polylactic acid and polyglycolic acid are crystalline, whereas those composed of racemic mixtures i.e. both levo and dextro rotatory forms are amorphous in nature. Furthermore, PLGA copolymers composed of less than 70% glycolic acid are known to be amorphous ([@b0045]). In the present study, we used D, L-PLGA (50:50) which exhibited amorphous nature in our X-ray diffraction study ([Fig. 9](#f0045){ref-type="fig"}b), showing consistency with the available literatures ([@b0150], [@b0045]). The XRD spectrum of baricitinib encapsulated PLGA nanoparticles ([Fig. 9](#f0045){ref-type="fig"}c) exhibited non-crystalline behaviour (amorphous nature) with almost no intense peak except 2 broad and diffused peaks with low intensity of approximately 385 and 393 counts at 19.3 and 23.2 degree respectively. This behaviour may be due to amorphization of crystalline baricitinib during nanoencapsulation within the PLGA polymer, causing loss of all high intensity peaks of crystalline baricitinib observed in [Fig. 9](#f0045){ref-type="fig"}a.Fig. 9X-ray diffractogram of (a) baricitinib, (b) PLGA and (c) baricitinib encapsulated PLGA nanoparticles.

### 3.3.3. Differential Scanning calorimetry of nanoparticles {#s0150}

Differential Scanning calorimetry of pure baricitinib and baricitinib encapsulated nanoparticles was performed to compare the characteristics of baricitinib before and after nano-encapsulation. The DSC thermograms of baricitinib and baricitinib encapsulated nanoparticles are presented in [Fig. 10](#f0050){ref-type="fig"}. These DSC thermogram of baricitinib ([Fig. 10](#f0050){ref-type="fig"}b) exhibited sharp characteristic endotherm (melting point peak) at 215.3 °C. However, thermogram of baricitinib encapsulated nanoparticles ([Fig. 10](#f0050){ref-type="fig"}a) exhibited only a short endotherm at 55.3 °C, which correspond to the glass transition temperature (Tg) of the polymer PLGA. The absence of a sharp characteristic endothermic peak of baricitinib indicated the encapsulation of drug within the polymer. Furthermore, the drug may be molecularly dispersed as an amorphous mixture within the polymer. The melting point rage of the baricitinib reported in literature is between 212 and 215 °C ([@b0065], [@b0025]). The melting point we observed in this study was 215.3 °C, which was very close to the reported values. Likewise, the glass transition temperature of polymer PLGA (50:50), we observed here (55.3 °C) is also very close to the reported values (45--55 °C) in the literature ([@b0115],)^.^Fig 10Differential Scanning calorimetry thermogram of (a) baricitinib encapsulated PLGA nanoparticles (b) baricitinib.

### 3.3.4. Fourier transform infra-red spectroscopy of PLGA nanoparticles {#s0155}

FT-IR spectroscopy of pure baricitinib and PLGA nanoparticles encapsulated with baricitinib was performed to find out any chemical or molecular interaction between the baricitinib and PLGA polymer. The FT-IR spectra of baricitinib and baricitinib encapsulated PLGA nanoparticles are presented in [Fig. 10](#f0050){ref-type="fig"}. The FT-IR spectrum of baricitinib ([Fig. 11](#f0055){ref-type="fig"}a) exhibited several strong absorption bands at wavenumbers of 3203.18, 3117.37, 2847.38, 2256.31, 1857.43 and 1579.41 cm^−1^, corresponding to N---H stretching, 000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000C---H stretching (aromatic), ---C---H stretching of the methyl/methylene groups, C000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000N stretching, CN stretching and CC (aromatic) stretching respectively. The spectrum of baricitinib encapsulated nanoparticles ([Fig. 11](#f0055){ref-type="fig"}b), did not exhibited the characteristic absorption bands which were observed in the spectrum of baricitinib ([Fig. 11](#f0055){ref-type="fig"}a), rather two weak absorption bands at 2889.81 and 1760.69 cm^−1^, which may be assigned to the ---C---H stretching and CO stretching of the methyl and carbonyl groups present in the PLGA polymer ([@b0060]). The absence of characteristic absorption bands of baricitinib in the spectrum of PLGA nanoparticles indicates physical entrapment of baricitinib in the nanoparticles.Fig 11FT-IR Spectra of (a) baricitinib and (b) baricitinib encapsulated PLGA nanoparticles.

### 3.3.5. *In vitro* release study of baricitinib encapsulated PLGA nanoparticles {#s0160}

The *in vitro* release studies of baricitinib and baricitinib encapsulated PLGA nanoparticles were conducted in phosphate buffer pH 6.8 with 0.5% w/v of sodium lauryl sulphate to maintain the sink condition and to mimic the *in vivo* environment. The *in vitro* release profiles of pure baricitinib and baricitinib encapsulated PLGA nanoparticles (F-8) are shown in [Fig. 12](#f0060){ref-type="fig"}. The PLGA nanoparticles exhibited biphasic release pattern with an initial burst release of baricitinib (38%) within 2 h followed by slow release of drug over a period of 24 h (93%). The burst release of the baricitinib from nanoparticles may be due to adsorbed drug on the surface of the PLGA polymer. The drug release during the sustained release phase may result from slow degradation of PLGA in the dissolution media.Fig. 12*In vitro* release profiles of baricitinib (▴) and baricitinib encapsulated PLGA nanoparticles, formulation F-8 (■) in phosphate buffer pH 6.8 with 0.5% w/v sodium lauryl sulphate.

The *in vitro* release data were fitted to various kinetic models to understand the mechanism of release of baricitinib from the PLGA nanoparticles. The drug release profile for baricitinib encapsulated nanoparticles was best fitted with Higuchi model as the regression coefficient (R2) was found to be the highest (0.918) for Higuchi model among the various kinetic models tested for the release profile ([Table 5](#t0025){ref-type="table"}).Table 5Kinetic models with kinetic release rate constants and correlation coefficients of *in vitro* release profile of baricitinib encapsulated PLGA nanoparticles.Kinetic models fittedCorrelation coefficients (R^2^)Release rate constantsZero order0.7081.409First order0.9110.279Hixson-Crowell0.8540.627Higuchi0.9180.549Korsmeyer Peppas0.5630.026

4. Conclusions {#s0165}
==============

The baricitinib encapsulated PLGA nanoparticles produced by nanoprecipitation method had small size with very low PDI and good entrapment efficiency. *In vitro* release profile exhibited a sustained release behaviour resulting in 89% release in 12-h period while 93% over 24-h period. PLGA polymer had more pronounced effect on sustaining the drug release rather than enhancing the solubility of the drug encapsulated. This sustained release behavior may be utilized for the management of chronic rheumatoid arthritis and may be helpful in reduction of side effects by minimizing the dose of baricitinib. We plan to conduct an efficacy study and or bioavailability studies in the animals in near future.
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[^1]: F-16 was prepared by suspending the drug in 1% pluronic 127.
